Autologous CAR-T cell therapy expressing the BAFF-ligand

N/A

Report date: 2023/05/05 18:02:05

Base Information

Drug NameAutologous CAR-T cell therapy expressing the BAFF-ligand
Drug Alias NameLMY-920LUMT1A22
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-cell-activating factor/B lymphocyte stimulator inhibitors
TargetsB-cell-activating factor/B lymphocyte stimulator
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicSjogren's Syndrome +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLuminary Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLuminary Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicSjogren's Syndrome +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A